On Saturday, 9 May 2026, Jiahui International Cancer Center (JICC) held a webinar entitled “Advancing Hematologic Oncology: CAR-T Innovations and Full-Cycle Clinical Care” which attracted the participation of 360 physicians from across Saudi Arabia. The webinar, which carried two Saudi Commission for Health Specialties CME credit points, discussed the latest developments in CAR-T therapy and the evolving landscape of advanced cancer treatment.

The webinar was led entirely by JICC physicians, with Dr. Hao Siguo, Chief Hematology Consultant, presenting on “Basics of CAR-T Therapy & Comprehensive Management of CAR-T Therapy”, and Dr. Xuan Linli, Chief of Medical Oncology at Jiahui International Cancer Center, presenting on “CAR-T Therapy in Solid Tumor & Autoimmune Diseases”. The sessions highlighted both the clinical foundations of CAR-T therapy and the expanding role of innovative cellular therapies beyond hematologic malignancies.

The webinar also reflected China’s growing role in medical innovation, advanced therapies, and internationally oriented healthcare delivery. Particular attention was given to the rapidly evolving field of CAR-T therapy, including the upcoming launch of the world’s first CAR-T treatment for solid tumors — a major milestone that further positions China at the forefront of next-generation cancer treatment and translational medicine.

The strong participation and engagement from physicians in Saudi Arabia further underline the growing international interest in China’s healthcare innovation ecosystem, multidisciplinary expertise, and access to cutting-edge therapies.

Through initiatives like these, JICC continues to strengthen cross-border medical exchange and contributes to deeper healthcare collaboration between China and the Middle East.